Delcasertib 是一种有效且选择性的 δ-蛋白激酶 C (δPKC) 抑制剂，可改善急性心肌梗死动物模型的缺血再灌注损伤。

Delcasertib is a potent and selective inhibitor of δ-protein kinase C (δPKC).

Delcasertib is composed of a selective δ-protein kinase C (δPKC) inhibitor peptide derived from the δV1-1 portion of δPKC (termed "cargo peptide”), conjugated reversibly to the cell-penetrating peptide 11-amino acid, arginine-rich sequence of the HIV type 1 transactivator protein (TAT47–57; termed "carrier peptide”) via a disulfide bond.

KAI-9803 ameliorates pathological conditions in acute myocardial infarction and reduce pain via specific modulation of membrane-translocation of PKC delta or epsilon. Delcasertib has an acceptable safety and tolerability profile when delivered via intracoronary injection during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.Delcasertib administration at the end of ischemia has been found to reduce cardiac damage caused by ischemia-reperfusion in a rat model of acute myocardial infarction. 14C-KAI-9803 is rapidly delivered to many tissues, including the heart (1.21 μg eq/g tissue), while being quickly cleared from the systemic circulation. The distribution of Delcasertib to tissues such as the liver, kidney, and heart is facilitated by the reversible conjugation to TAT47–57.

949100-39-4

C120H199N45O34S2

2880.28

KAI-9803;BMS-875944

DMSO:99 mg/mL(34.37 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years